αENaC Activators
αENaC activators represent a diverse array of chemical entities characterized by their distinct capacity to modulate the activity of the epithelial sodium channel (αENaC) in renal epithelial cells. The αENaC, a critical player in renal sodium homeostasis, serves as the primary mediator of sodium reabsorption in the distal nephron. Among the identified activators, Amiloride and Benzamil, classified as potassium-sparing diuretics, indirectly engage αENaC by disrupting sodium balance within the distal nephron. These compounds achieve this modulation by either inhibiting sodium reabsorption or directly blocking ENaCs, culminating in the enhanced expression and augmented activity of αENaC. Concurrently, hormones such as aldosterone, Hydrocortisone, and Fludrocortisone act as direct activators, engaging αENaC through binding to mineralocorticoid receptors. This interaction triggers a cascade leading to transcriptional upregulation of αENaC, fostering increased sodium reabsorption.
Glucocorticoids, represented by Dexamethasone and Hydrocortisone, adopt an indirect activation mechanism by influencing the expression of regulatory proteins, including the inhibition of NF-κB. In a similar vein, Naringenin and Resveratrol, classified as flavonoids and polyphenols, respectively, indirectly activate αENaC through the inhibition of SGK1, a kinase negatively regulating ENaC. This indirect modulation alleviates the inhibitory constraints on αENaC, resulting in heightened expression and augmented activity. Spironolactone, an aldosterone antagonist, introduces indirect activation of αENaC by impeding the effects of aldosterone. This alteration in sodium balance subsequently amplifies αENaC expression and activity. Loop diuretics, exemplified by Torasemide and Bumetanide, indirectly activate αENaC by promoting diuresis, triggering an increase in aldosterone secretion and consequent enhancement of αENaC expression and activity. Collectively, this diverse array of αENaC activators provides invaluable insights into the intricate regulatory mechanisms governing sodium balance within renal epithelial cells. The multifaceted mechanisms employed by these chemicals underscore the complexity of the regulatory networks orchestrating electrolyte homeostasis in the kidney, offering potential avenues for the development of modulators targeting sodium reabsorption in the distal nephron.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Aldosterone | 52-39-1 | sc-210774 sc-210774A sc-210774B sc-210774C sc-210774D sc-210774E | 2 mg 5 mg 10 mg 50 mg 100 mg 250 mg | $259.00 $213.00 $317.00 $1550.00 $3074.00 $7637.00 | 1 | |
Aldosterone, a mineralocorticoid hormone, directly activates αENaC by binding to mineralocorticoid receptors in renal tubular cells. This binding induces transcriptional upregulation of αENaC, increasing its expression and enhancing sodium reabsorption. Aldosterone's specific action on mineralocorticoid receptors in the distal nephron highlights its pivotal role in directly modulating αENaC activity, promoting sodium retention, and maintaining electrolyte homeostasis. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone, a synthetic glucocorticoid, indirectly activates αENaC by modulating the expression of regulatory proteins. This involves the inhibition of NF-κB, a transcription factor that negatively regulates αENaC. By suppressing NF-κB, Dexamethasone relieves the inhibitory constraint on αENaC, leading to increased expression and activity. | ||||||
Hydrocortisone | 50-23-7 | sc-300810 | 5 g | $102.00 | 6 | |
Hydrocortisone, a natural glucocorticoid, indirectly activates αENaC by modulating the expression of regulatory proteins. This involves the inhibition of NF-κB, a transcription factor that negatively regulates αENaC. By suppressing NF-κB, Hydrocortisone relieves the inhibitory constraint on αENaC, leading to increased expression and activity. | ||||||
Fludrocortisone | 127-31-1 | sc-207690 | 50 mg | $454.00 | ||
Fludrocortisone, a synthetic mineralocorticoid, directly activates αENaC by binding to mineralocorticoid receptors in renal tubular cells. This binding induces transcriptional upregulation of αENaC, increasing its expression and enhancing sodium reabsorption. Fludrocortisone's specific action on mineralocorticoid receptors in the distal nephron highlights its pivotal role in directly modulating αENaC activity, promoting sodium retention, and maintaining electrolyte homeostasis. | ||||||
Naringenin | 480-41-1 | sc-219338 | 25 g | $245.00 | 11 | |
Naringenin, a flavonoid, indirectly activates αENaC by inhibiting SGK1, a kinase that negatively regulates ENaC. By suppressing SGK1 activity, Naringenin relieves the inhibitory constraint on αENaC, leading to increased expression and activity. This interaction with SGK1 underscores Naringenin's role in modulating αENaC function, providing a unique avenue for the regulation of sodium reabsorption in renal epithelial cells. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol, a polyphenol, indirectly activates αENaC by inhibiting SGK1, a kinase that negatively regulates ENaC. By suppressing SGK1 activity, Resveratrol relieves the inhibitory constraint on αENaC, leading to increased expression and activity. This interaction with SGK1 underscores Resveratrol's role in modulating αENaC function, providing a unique avenue for the regulation of sodium reabsorption in renal epithelial cells. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Spironolactone, an aldosterone antagonist, indirectly activates αENaC by blocking the effects of aldosterone. By inhibiting aldosterone, Spironolactone reduces sodium reabsorption and enhances αENaC expression and activity. This aldosterone antagonism showcases Spironolactone's ability to alter sodium balance and modulate αENaC function in renal epithelial cells, providing a unique avenue for the regulation of sodium reabsorption in the distal nephron. | ||||||
Torsemide | 56211-40-6 | sc-213059 | 10 mg | $260.00 | ||
Torasemide, a loop diuretic, indirectly activates αENaC by promoting diuresis. Enhanced sodium and water excretion result in reduced blood volume and cardiac output, leading to increased aldosterone secretion. Elevated aldosterone enhances αENaC expression and activity, promoting sodium reabsorption. Torasemide's impact on the overall balance of fluid and electrolytes underscores its role in indirectly modulating αENaC function in renal epithelial cells. | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $109.00 $228.00 | 9 | |
Bumetanide, a loop diuretic, indirectly activates αENaC by promoting diuresis. Enhanced sodium and water excretion result in reduced blood volume and cardiac output, leading to increased aldosterone secretion. Elevated aldosterone enhances αENaC expression and activity, promoting sodium reabsorption. Bumetanide's impact on the overall balance of fluid and electrolytes underscores its role in indirectly modulating αENaC function in renal epithelial cells. | ||||||